Details for New Drug Application (NDA): 216344
✉ Email this page to a colleague
The generic ingredient in POTASSIUM PHOSPHATES is potassium phosphate, dibasic; potassium phosphate, monobasic. There are two hundred and forty drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the potassium phosphate, dibasic; potassium phosphate, monobasic profile page.
Summary for 216344
Tradename: | POTASSIUM PHOSPHATES |
Applicant: | Amneal |
Ingredient: | potassium phosphate, dibasic; potassium phosphate, monobasic |
Patents: | 0 |
Pharmacology for NDA: 216344
Mechanism of Action | Osmotic Activity |
Physiological Effect | Increased Large Intestinal Motility Inhibition Large Intestine Fluid/Electrolyte Absorption |
Suppliers and Packaging for NDA: 216344
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
POTASSIUM PHOSPHATES | potassium phosphate, dibasic; potassium phosphate, monobasic | SOLUTION;INTRAVENOUS | 216344 | ANDA | Amneal Pharmaceuticals Private Limited | 80830-1691 | 80830-1691-2 | 10 VIAL, SINGLE-DOSE in 1 CARTON (80830-1691-2) / 15 mL in 1 VIAL, SINGLE-DOSE (80830-1691-1) |
POTASSIUM PHOSPHATES | potassium phosphate, dibasic; potassium phosphate, monobasic | SOLUTION;INTRAVENOUS | 216344 | ANDA | Amneal Pharmaceuticals Private Limited | 80830-1691 | 80830-1691-5 | 25 VIAL, SINGLE-DOSE in 1 CARTON (80830-1691-5) / 15 mL in 1 VIAL, SINGLE-DOSE (80830-1691-1) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAVENOUS | Strength | 1.18GM/5ML (236MG/ML);1.12GM/5ML (224MG/ML) | ||||
Approval Date: | Oct 10, 2023 | TE: | AP | RLD: | No |
Profile for product number 002
Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAVENOUS | Strength | 3.54GM/15ML (236MG/ML);3.36GM/15ML (224MG/ML) | ||||
Approval Date: | Oct 10, 2023 | TE: | AP | RLD: | No |
Profile for product number 003
Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAVENOUS | Strength | 11.8GM/50ML (236MG/ML);11.2GM/50ML (224MG/ML) | ||||
Approval Date: | Oct 10, 2023 | TE: | AP | RLD: | No |
Complete Access Available with Subscription